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Abstract
Background: Parathyroid carcinoma (PC) is a very rare malignancy with a high tendency to recur locally, and
recurrent disease is difficult to eradicate. In most western European countries and United States, these malignant
neoplasms cause less than 1% of the cases with primary hyperparathyroidism, whereas incidence as high as 5%
have been reported from Italy, Japan, and India. The molecular etiology of PC is poorly understood.
Results: The APC (adenomatous polyposis coli) tumor suppressor gene was inactivated by DNA methylation in five
analyzed PCs, as determined by RT-PCR, Western blotting, and quantitative bisulfite pyrosequencing analyses. This
was accompanied by accumulation of stabilized active nonphosphorylated b-catenin, strongly suggesting aberrant
activation of the WNT/b-catenin signaling pathway in these tumors. Treatment of a primary PC cell culture with the
DNA hypomethylating agent 5-aza-2’-deoxycytidine (decitabine, Dacogen(r)) induced APC expression, reduced
active nonphosphorylated b-catenin, inhibited cell growth, and caused apoptosis.
Conclusion: Aberrant WNT/b-catenin signaling by lost expression and DNA methylation of APC, and accumulation
of active nonphosphorylated b-catenin was observed in the analyzed PCs. We suggest that adjuvant epigenetic
therapy should be considered as an additional option in the treatment of patients with recurrent or metastatic
parathyroid carcinoma.
Background
Parathyroid carcinoma (PC) is a rare cause of primary
hyperparathyroidism with characteristic marked hypercal-
cemia and highly elevated parathyroid hormone levels. In
most western European countries and United States, these
malignant neoplasms cause less then 1% of the cases,
whereas incidence as high as 5% have been reported from
Italy, Japan, and India [1-4]. The incidence in the United
States has more than doubled since 1988 [5]. PCs are
slow-growing with a high tendency to recur locally
(30%-50%), and recurrent disease is difficult to eradicate
[6-8]. An overall 5-year survival rate of 86% and a 10-year
survival rate of 49% have been observed in a report that
described 286 cases of PC in the United States [9].
Loss of heterozygocity analyses have shown a higher
fractional allelic loss in PCs than in parathyroid adeno-
mas, where frequently deleted regions included the
PTEN, RB, HRAS, p53, MEN1, and HRPT2 genes
[10,11]. Somatic MEN1 mutations were recently
described in 3 of 23 (13%) PCs, suggesting a role in the
development of these tumors [12]. Overexpression of the
cyclin D1 oncogene (CCND1) has been observed in 10 of
11 (91%) PC specimens [13]. Carriers of the hyperpar-
athyroidism-jaw tumor (HPT-JT) syndrome show a
higher risk of developing PC; 10% to 15% of affected indi-
viduals present with malignant parathyroid tumors [14].
Somatic mutations of HRPT2 (parafibromin), the gene
responsible for HPT-JT syndrome [14], occur in PC with
an estimated odds ratio of 45.2 (95% CI: 12.8-160.0%) as
calculated from a compilation of six published studies.
The HRPT2 mutation frequency in sporadic parathyroid
adenoma was calculated to 1.8% [15].
Negative immunostaining for parafibromin has been
suggested as a means to diagnose PC, if the rare com-
monly cystic adenomas of the HPT-JT syndrome are
excluded [16,17]. Recently, it was suggested that this
may have some limited validity and cannot replace
HRPT2 mutation analysis [18]. Positive immunostaining
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for PGP9.5 (UCHL1) as well as absent staining for the
adenomatous polyposis coli (APC) tumor suppressor
have been suggested recently as additional markers for
parathyroid malignancy [19,20].
Inactivation of APC by mutation with subsequent stabi-
lization of b-catenin has been strongly implicated in the
cause of approximately 80% of colorectal cancers [21-24].
APC function can also be impaired by reduced expression
through hypermethylation of the APC 1A promoter, a
phenomenon observed in several malignances [25-29].
In the present study, we show that absent or markedly
reduced expression of APC in five analyzed PCs is
caused by hypermethylation of the APC promoter 1A.
We also show that this was accompanied by accumula-
tion of stabilized active nonphosphorylated b-catenin,
strongly suggesting aberrant activation of the WNT/b-
catenin signaling pathway in these tumors. Treatment of
a primary PC cell culture with the DNA hypomethylat-
ing agent 5-aza-2’-deoxycytidine induced APC expres-
sion, reduced active nonphosphorylated b-catenin,
inhibited cell growth, and caused apoptosis. 5-aza-2’-
deoxycytidine (decitabine; Dacogen; MGI Pharma, Bloo-
mington, MN) was recently approved by the United
States Food and Drug Administration for the treatment
of myelodysplastic syndrome [30,31]. We suggest that
epigenetic therapy should be considered as an additional




Tissue specimens were acquired from patients diagnosed
and operated on in the clinical routine at Uppsala Uni-
versity Hospital and Martin-Luther-University of Halle-
Wittenberg. The tissue was intraoperatively snap frozen.
Normal parathyroid tissue was obtained from glands
inadvertently removed in conjunction with thyroid sur-
gery where autotransplantation was not required (n = 1)
or as normal parathyroid gland biopsies in patients sub-
jected to parathyroidectomy (n = 7). The diagnosis of
parathyroid carcinoma (n = 5) was unequivocal due to
occurrence of distant metastases at diagnosis or follow-
up. Clinical characteristics of four PC patients have
been published [32]. Written informed consent was
obtained from the patients and approval was obtained
from the local ethical committee, Uppsala.
DNA and RNA preparation, RT-PCR
DNA was prepared from cryosections using QIAamp(r)
DNA Mini Kit (Qiagen) and total RNA using TriZol
Reagent (Gibco BRL, Life Technologies Inc.), according to
the manufacturer’s instructions. DNA-free RNA was pre-
pared using the Nucleospin RNA II kit (Macherey-Nagel
GmbH & Co. KG). Reverse transcription of RNA was
performed with random hexamer primers using the First-
Strand cDNA Synthesis kit (GE Healthcare) according to
the manufacturer’s instructions. RT-PCR of APC was
performed using the forward primer 5’-gccagctcctgttgaa-
catcagat (exon 11) and the reverse primer 5-gcccatacattt-
cacagtccactt (exon 12). The PCR resulted in a 150 base
pair fragment. Primers for GAPDH were as described pre-
viously [32].
Quantitative RT-PCR
Quantitative real-time PCR was performed on StepOne-
Plus™ Real-Time PCR systems (Applied Biosystems, Fos-
ter City, CA) using assays for APC (Hs 01568270_m1)
and GAPDH (Hs99999905_m1). Each cDNA sample
was analyzed in triplicate. Standard curves were estab-
lished by amplifying a purified PCR fragment covering
the sites for probes and primers.
Immunohistochemistry
Frozen tissue sections were stained as described [33]
using an anti-APC mouse monoclonal antibody with an
epitope mapping at the N-terminus (Santa Cruz Bio-
technology, INC., Santa Cruz, CA; catalog no. sc-9998).
DNA sequencing
All APC coding exons 2-15 with intron/exon junctions
were directly sequenced on the 3130xl Genetic Analyzer
using the Big Dye(r) terminator v1.1 cycle sequencing
kit (Applied Biosystems, Foster City, CA). PCR primers
for exon 10 and exon 14 [34], and the additional ones
[35] were as published. The known C/T (exon 12; posi-
tion 14577867) and G/A polymorphisms (exon 14; posi-
tion 14579574) were found in three and five of the
analyzed PCs, respectively. No mutations were observed.
Bisulfite pyrosequencing
DNA was converted using the EpiTect Bisulfite Kit and
PCR amplified using the HotStarTaq Plus Master Mix
Kit (Qiagen). The APC assay used is available at the
PyroMark Assay Database (Qiagen). Pyrosequencing
[36-38] was done with the PyroMark™ Q24 system (Qia-
gen). All samples were analyzed in triplicates (Additional
file 1: Table S1).
Western blotting analysis
Western blotting analyses were done on extracts pre-
pared in Cytobuster Protein Extract Reagent (Novagen
Inc., Madison, Wisconsin, USA) or RIPA buffer supple-
mented with Complete protease inhibitor cocktail (Roche
Diagnostics GmbH, Mannheim, Germany). Anti-b-cate-
nin goat polyclonal antibody (Santa Cruz Biotechnology
Inc., Santa Cruz, USA, # sc-1496), anti-active-b-catenin
[39] (Upstate, Lake Placid, USA, # 05-665), anti-APC rab-
bit polyclonal antibody (Santa Cruz Biotechnology Inc.,
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Santa Cruz, USA, # sc-896), and anti-b-tubulin polyclo-
nal antibody (Santa Cruz Biotechnology Inc.) were used.
After incubation with the appropriate secondary antibo-
dies, bands were visualized using the enhanced chemilu-
minescence system (GE Healthcare Europe GmbH,
Uppsala, Sweden).
Cell culture
Parathyroid carcinoma cells (PC1) were prepared
directly after operation according to published proce-
dures [40]. Collagenase digestion was for 1 hour. Cells
(2×105) were distributed onto 35-mm dishes in DMEM/
10% fetal bovine serum (Sigma) and incubated in tripli-
cates with 5 μM 5-aza-2’-deoxycytidine (Sigma-Aldrich).
Fresh 5-aza-2’-deoxycytidine was added every 24 hrs.
Cells were harvested after 24 hrs and 48 hrs for RNA
and protein extraction. Cell viability was measured on
PC1 cells distributed in triplicates (2×104) onto 96 well
plates using the cell proliferation reagent WST-1 (Roche
Diagnostics GmbH, Mannheim, Germany). Quantifica-
tion of cytoplasmic histone-associated-DNA-fragments
(mono- and oligonucleosomes) was done using the Cell
Death Detection ELISA PLUS kit (Roche Diagnostics).
Camptothecin at 0.1 μg/ml was used as positive control
of apoptosis.
Statistical analysis
Unpaired t test was used. Values are presented as arith-
metical mean ± SEM. A p value of < 0.05 was consid-
ered significant.
Results and Discussion
APC promoter hypermethylation in parathyroid
carcinoma
In order to determine whether expression of APC was
perturbed in the five PC specimens, RT-PCR analysis was
performed. The results showed that APC mRNA expres-
sion was undetectable to very low in the PCs when com-
pared to parathyroid adenomas or normal parathyroid
tissue specimens (Figure 1A). In agreement, APC protein
expression was undetectable in the five PCs as revealed
by Western blotting analysis (Figure 1B) and immunohis-
tochemistry (data not shown). Gene inactivation or
reduced expression could be caused by various mechan-
isms, including promoter hypermethylation. We used
Figure 1 Expression of APC mRNA and protein. A, RT-PCR
analysis of parathyroid carcinomas (PC1-5), parathyroid adenomas
(PA1-3), and normal parathyroid tissue specimens (PN1-5). B,























CpG 1 CpG 2 CpG 3 CpG 4 CpG 5 CpG 6 CpG 7 CpG 8 CpG 9 CpG 10
PN PC PN PC PN PC PN PC PN PC PN PC PN PC PN PC PN PC
Figure 2 DNA methylation analysis by quantitative bisulfite pyrosequencing. Parathyroid carcinomas (in red; n = 5) and normal
parathyroid tissue specimens (in blue; n = 8). Methylation levels were determined for ten CpGs of the APC promoter 1A, in triplicates. See
Additional file 1, Table S1 for all measurements.
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bisulfite pyrosequencing to quantitatively determine the
methylation level for ten CpGs of the APC promoter 1A
(Figure 2; Additional file 1, Table S1). The mean methy-
lation levels (%) of all CpGs were significantly higher in
the five PCs (48%-88%) than in the eight normal para-
thyroid tissue specimens (10%-18%). It is conceivable
that the increased methylation level of the APC promoter
caused the prominent reduction in gene expression.
This was further supported by in vitro cell culturing
experiments (Figure 3). Treatment of cultured primary
cells from parathyroid carcinoma no. 1 (PC1) with the
DNA methylation inhibitor 5-aza-2’-deoxycytidine (deci-
tabine, Dacogen(r)) resulted in apparent induction of
APC mRNA and protein expression, and as expected [41]
also in reduced cell viability and apoptosis (Figure 3A-D).
Thus, a mean APC methylation level of 48% (PC1; Addi-
tional file 1, Table S1) seemed sufficient for “gene inacti-
vation”. We note that this is in agreement with a recent
report on a number of hypermethylated genes in colon
cancer where methylation levels in excess of 40% were
found to be incompatible with transcription [42]. We
also performed DNA sequencing analysis of all APC
exons and intron/exon splice junctions in the five PCs,
with no detected mutations (data not shown).
Accumulation of active nonphosphorylated b-catenin in
parathyroid carcinoma
Mutation or vanished expression of APC may lead to
aberrant activation of the WNT/b-catenin signaling
pathway, through the accumulation of stabilized active
nonphosphorylated b-catenin [21-24]. Western blotting
analyses with antibodies to total b-catenin or to active
nonphosphorylated b-catenin [39] showed almost similar
relative protein levels in the five PCs (Figure 4A; B). On
the contrary, in normal parathyroid tissue specimens
(Figure 4B) the expression level of active nonphosphory-
lated b-catenin was lower than the total b-catenin level,
and much lower than in the parathyroid carcinomas.
These results strongly suggest the presence of accumu-
lated active nonphosphorylated b-catenin in the ana-
lyzed PCs. Among its many functions APC controls the
level of b-catenin [21-24]. We reasoned that if the
strongly reduced expression of APC (Figure 1A-B)
caused accumulation of active b-catenin, then re-expres-
sion of APC in cultured primary PC1 cells by treatment
with the general demethylating agent 5-aza-2’-deoxycyti-
dine (Figure 3A-B) should lead to a reduced active
b-catenin level. A reduced active b-catenin level was
observed (Figure 4C). This result is consistent with the
normal role for APC in regulating the b-catenin level.
For all five analyzed PCs, our results strongly suggest
inactivation of APC by DNA methylation and conse-
quential aberrant WNT/b-catenin signaling by the accu-
mulation of active nonphosphorylated b-catenin.
Treatment in vitro with the hypomethylating agent
5-aza-2’-deoxycytidine inhibited PC cell growth and
induced apoptosis, raising hopes for adjuvant therapy.
A recent study demonstrated negative immunohisto-
chemical staining for APC in nine of twelve PCs [20],
supporting a frequent inactivation of APC in PCs.
The only treatment of PC with higher rate of cure is
diagnosis before or during operation followed by com-
plete removal of the tumor. Treatments of recurrent or
metastatic disease have been difficult to evaluate due to
the uncommonness of the tumor entity, but in one study
Figure 3 Effects of 5 μM 5-aza-2’-deoxycytidine (Aza) on in
vitro cultured primary parathyroid carcinoma cells (PC1). A,
APC/GAPDH mRNA expression ratio as determined by real-time
quantitative RT-PCR analysis. B, Western blotting analysis of APC.
Coomassie blue-stained filter is shown as loading control. C, cell
viability. D, apoptosis. Camptothecin at 0.1 μg/ml was used as
positive control.
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adjuvant radiotherapy was shown to improve survival
[43]. 5-aza-2’-deoxycytidine (decitabine; Dacogen; MGI
Pharma, Bloomington, MN) was recently approved by
the United States Food and Drug Administration for the
treatment of myelodysplastic syndrome [30,31]. 5-aza-2’-
deoxycytidine has been shown to suppress tumorigene-
city of xenografted cells from solid tumors [41,44-46].
Although its efficacy in solid tumors remains to be fully
evaluated [31,47], we suggest that Dacogen(r) should be
taken under consideration for additional treatment of
recurrent or metastatic PC, a life threatening condition
which has been notoriously difficult to eradicate.
Conclusions
The WNT/b-catenin signaling pathway was aberrantly acti-
vated in the analyzed parathyroid carcinomas, due to lost
expression of APC likely caused by promoter DNA methy-
lation. APC was reactivated in vitro by 5-aza-2’-deoxycyti-
dine and adjuvant epigenetic therapy (decitabine; Dacogen;
MGI Pharma, Bloomington, MN) should be considered as
an additional option in the treatment of patients with
recurrent or metastatic parathyroid carcinoma.
Additional material
Additional file 1: Table S1 - Quantitative bisulfite pyrosequencing
of 10 CpGs in the APC promoter 1A. Normal parathyroid tissue
specimens (PN, n = 8) and parathyroid carcinoma (PC, n = 5) were
analyzed in triplicate.
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